CANNN

Cannabis Science Inc (OTCMKTS:CBIS) Enters Into A Deal With Derwin A. Wallace

Cannabis Science Inc (OTCMKTS:CBIS) entered into a one-year alliance with Derwin A. Wallace. As per the terms, Wallace will be accountable for financial as well as investor relations services. The prime attention will remain on extending and managing the financial communications with the institutional as well as retail investment groups and handle coverage from key research analysts as an important part of financial and investor relations plan.

The responsibilities

Expressing his perspective on the new profile, Mr. Wallace said that he will put his best measures to expedite Cannabis Science under development processes. His main focus will be to have a transparent communication with the company’s shareholders and throw light on the ongoing and scheduled drug development plans, planned patient education systems and make available all the required information on product launches in motion.

The objectives

Wallace explained that his initiatives would be focused to pace up Cannabis Science ongoing development plans. Overall, it would prompt the company to secure a sustainable and adequate operational cash flow. As of now, there are a number of ongoing projects at the moment, including the product launch in different locations, then project pertaining to Netherlands pre-lab discussions.

The projects

The other plans include drug development projects underway in Italy, Africa and London. Also, there are other projects related to formulation releases in Washington and Colorado. The company expects strong revenue generation from the ongoing projects. It not only reflects the company’s growth but also focus on the strong growth in medical marijuana industry.

The significance

Mr. Raymond C. Dabney of Cannabis Science expressed that the alliance with Wallace throws light on the company’s dedication towards shareholders. The goal is to add value by setting into motion the capital of $5 million – $25 million and go for cash generation required to take the firm to the next level.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 traders350.com. All RIGHTS RESERVED.